Targeting the dopamine D1 receptor or its downstream signalling by inhibiting phosphodiesterase-1 improves cognitive performance

23Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background and Purpose: Insufficient prefrontal dopamine 1 (D1) receptor signalling has been linked to cognitive dysfunction in several psychiatric conditions. Because the PDE1 isoform B (PDE1B) is postulated to regulate D1 receptor-dependent signal transduction, in this study we aimed to elucidate the role of PDE1 in cognitive processes reliant on D1 receptor function. Experimental Approach: Cognitive performance of the D1 receptor agonist, SKF38393, was studied in the T-maze continuous alternation task and 5-choice serial reaction time task. D1 receptor/PDE1B double-immunohistochemistry was performed using human and rat prefrontal brain sections. The pharmacological activity of the PDE1 inhibitor, ITI-214, was assessed by measuring the increase in cAMP/cGMP in prefrontal brain tissue and its effect on working memory performance. Mechanistic studies on the modulation of prefrontal neuronal transmission by SKF38393 and ITI-214 were performed using extracellular recordings in brain slices. Key Results: SKF38393 improved working memory and attentional performance in rodents. D1 receptor/PDE1B co-expression was verified in both human and rat prefrontal brain sections. The pharmacological activity of ITI-214 on its target, PDE1, was demonstrated by its ability to increase prefrontal cAMP/cGMP. In addition, ITI-214 improved working memory performance. Both SKF38393 and ITI-214 facilitated neuronal transmission in prefrontal brain slices. Conclusion and Implications: We hypothesize that PDE1 inhibition improves working memory performance by increasing prefrontal synaptic transmission and/or postsynaptic D1 receptor signalling, by modulating prefrontal downstream second messenger levels. These data, therefore, support the use of PDE1 inhibitors as a potential approach for the treatment of cognitive dysfunction.

References Powered by Scopus

Improving bioscience research reporting: The arrive guidelines for reporting animal research

5688Citations
N/AReaders
Get full text

Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use

1568Citations
N/AReaders
Get full text

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: Updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

1531Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond

240Citations
N/AReaders
Get full text

Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules

35Citations
N/AReaders
Get full text

Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities

32Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Pekcec, A., Schülert, N., Stierstorfer, B., Deiana, S., Dorner-Ciossek, C., & Rosenbrock, H. (2018). Targeting the dopamine D1 receptor or its downstream signalling by inhibiting phosphodiesterase-1 improves cognitive performance. British Journal of Pharmacology, 175(14), 3021–3033. https://doi.org/10.1111/bph.14350

Readers over time

‘18‘19‘20‘21‘22‘23‘240481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 12

63%

Professor / Associate Prof. 4

21%

Researcher 3

16%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 3

25%

Neuroscience 3

25%

Agricultural and Biological Sciences 3

25%

Psychology 3

25%

Article Metrics

Tooltip
Mentions
References: 1

Save time finding and organizing research with Mendeley

Sign up for free
0